Genfit S.A. (GNFTF) Research

Genfit S.A. is a biopharmaceutical company primarily engaged in the discovery and development of innovative therapeutic candidates and diagnostic tools, specifically targeting metabolic and various liver-related conditions. Its lead drug candidate, Elafibranor, is currently in a Phase 3 clinical trial for the treatment of primary biliary cholangitis (PBC). Another asset, GNS561, is progressing through Phase 1b/2 trials for cholangiocarcinoma (CCA). Additionally, Nitazoxanide is undergoing a Phase 1 study to address acute-on-chronic liver failure. Beyond therapeutics, Genfit is also developing NIS4 technology, a diagnostic solution aimed at identifying nonalcoholic steatohepatitis (NASH) and fibrosis. Furthermore, it has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Its strategic collaborations also include a partnership with Genoscience Pharma for the development and commercialization of the investigational CCA treatment, GNS561. Established in 1999, Genfit S.A. operates from its headquarters in Loos, France.

Open Genfit S.A. (GNFTF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.